Lifesci Capital Begins Coverage on Obsidian Therapeutics (NASDAQ:OBX)

Investment analysts at Lifesci Capital began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX) in a research report issued on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $43.00 price target on the stock. Lifesci Capital’s price target points to a potential upside of 145.29% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Piper Sandler initiated coverage on shares of Obsidian Therapeutics in a research note on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price target for the company. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a research report on Thursday, August 6th. Finally, TD Cowen assumed coverage on Obsidian Therapeutics in a research note on Thursday, August 6th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Obsidian Therapeutics Price Performance

Shares of OBX opened at $17.53 on Tuesday. Obsidian Therapeutics has a 52-week low of $14.57 and a 52-week high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for cancer and other serious diseases. The company’s approach is designed to improve the safety, control and effectiveness of therapeutic proteins and genetic medicines by enabling their activity to be regulated inside the body.

Obsidian’s technology platform, known as cytoDRiVE, uses small-molecule-controlled genetic systems to modulate the expression or activity of therapeutic proteins.